American journal of hematology

publication venue for

Erythropoietin-secreting metanephric adenoma presenting as erythrocytosis. 2023
Angioimmunoblastic T-cell lymphoma presenting with severe plasmacytosis mimicking plasma cell leukemia. 2023
Acute Hemolytic Anemia After Hematopoietic Stem Cell Transplantation: An Unusual Invader. 2023
Disseminated intravascular coagulation due to cytomegalovirus infection in an immunocompetent adult treated with plasma exchange. 2006
Spurious fibrinogen levels secondary to pyroglobulinemia in Waldenström's macroglobulinemia. 1995
Lymphoma of host origin in a marrow transplant recipient in remission of acute myeloid leukemia and receiving cyclosporin A. 1985
Unusual intracytoplasmic inclusions in acute myeloblastic leukemia. 1980
Inherited combined deficiency of factor V and factor VIII: report of a case with normal factor VIII antigen and ristocetin-induced platelet aggregation. 1977
Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open-label study. 2024
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes. 2024
Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemia. 2023
Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel. 2023
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers. 2023
Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach. 2023
Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.. 98. 2022
Romiplostim use in pregnant women with immune thrombocytopenia. 2022
Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European society of blood and marrow transplantation.. 97. 2022
Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma.. 96. 2021
Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. 2021
Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts.. 96. 2021
Comprehensive phenotyping of erythropoiesis in human bone marrow: Evaluation of normal and ineffective erythropoiesis.. 96. 2021
Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.. 96. 2021
A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.. 96. 2020
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease.. 95. 2020
The clinical and pathological features of plasma cell myeloma post solid organ transplantation.. 95. 2020
Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation. 2020
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.. 95. 2020
Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403.. 95. 2020
Diagnostic workup of acute leukemias of ambiguous lineage.. 95. 2020
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma.. 95. 2020
Hemoglobin levels and coronary heart disease risk by age, race, and sex in the reasons for geographic and racial differences in stroke study (REGARDS).. 95. 2019
Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma.. 94. 2019
Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients.. 94. 2019
High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia.. 94. 2019
Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes.. 94. 2019
Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry.. 94. 2019
Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma.. 94. 2019
Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma.. 94. 2019
Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study.. 94. 2018
Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.. 93. 2018
Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial.. 94. 2018
Clinical and metabolomic risk factors associated with rapid renal function decline in sickle cell disease.. 93. 2018
Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T-ALL like mutations.. 93. 2018
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.. 93. 2018
Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R.. 93. 2018
Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study.. 93. 2018
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.. 93. 2018
Physician decision making in selection of second-line treatments in immune thrombocytopenia in children.. 93. 2018
T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.. 93. 2018
Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation.. 93. 2017
Safety and pharmacokinetics of the oral iron chelator SP-420 in β-thalassemia.. 92. 2017
European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia.. 92. 2017
Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.. 92. 2017
ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT.. 92. 2017
IgM myeloma: A multicenter retrospective study of 134 patients.. 92. 2017
Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT.. 92. 2017
Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia.. 92. 2017
Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT.. 92. 2017
Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration.. 91. 2016
Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia.. 91. 2016
De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.. 91. 2016
Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States.. 91. 2016
Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib.. 91. 2016
Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?. 91. 2016
Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?. 90. 2015
Red blood cell transfusion is associated with increased hemolysis and an acute phase response in a subset of critically ill children.. 90. 2015
Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma.. 90. 2015
Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.. 90. 2015
Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia.. 89. 2014
Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy.. 89. 2014
Pregnancy outcomes in women with thalassemia in North America and the United Kingdom.. 88. 2013
Transcriptomic and phospho-proteomic analyzes of erythroblasts expanded in vitro from normal donors and from patients with polycythemia vera.. 88. 2013
Longitudinal monitoring of cardiac siderosis using cardiovascular magnetic resonance T2* in patients with thalassemia major on various chelation regimens: a 6-year study.. 88. 2013
Regulatory B-cell compartment in transfused alloimmunized and non-alloimmunized patients with sickle cell disease.. 88. 2013
Exploring the amyloid proteome in immunoglobulin-derived lymph node amyloidosis using laser microdissection/tandem mass spectrometry.. 88. 2013
Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib.. 88. 2013
Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study.. 88. 2013
Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age.. 88. 2012
The clinical spectrum of Castleman's disease.. 87. 2012
Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma.. 87. 2012
Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients.. 87. 2012
Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma.. 87. 2012
Immune regulation in chronically transfused allo-antibody responder and nonresponder patients with sickle cell disease and β-thalassemia major.. 86. 2011
Iron chelation adherence to deferoxamine and deferasirox in thalassemia.. 86. 2011
Prognostic factors in patients with HIV-associated peripheral T-cell lymphoma: a multicenter study.. 86. 2011
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.. 85. 2010
The outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes.. 85. 2010
Repeated courses of rituximab in chronic ITP: Three different regimens.. 84. 2009
Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.. 84. 2009
Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma.. 84. 2009
Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma.. 84. 2009
Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura.. 83. 2008
Combined neonatal blood transplants in a parent-to-F1 mouse model: improved survival rates and stable long-term engraftment.. 82. 2007
Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis.. 82. 2007
Superior effect of intravenous anti-D compared with IV gammaglobulin in the treatment of HIV-thrombocytopenia: results of a small, randomized prospective comparison.. 82. 2007
Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload.. 82. 2007
Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura.. 82. 2007
Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma.. 81. 2006
Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura.. 81. 2006
Ikaros increases normal apoptosis in adult erythroid cells.. 81. 2006
Prospective evaluation of a new platelet glycoprotein (GP)-specific assay (PakAuto) in the diagnosis of autoimmune thrombocytopenia (AITP).. 78. 2005
Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies.. 76. 2004
Zileuton, a 5-lipoxygenase inhibitor, increases production of thromboxane A2 and platelet aggregation in patients with asthma.. 74. 2003
Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP).. 72. 2003
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.. 67. 2001
Do the acute platelet responses of patients with immune thrombocytopenic purpura (ITP) to IV anti-D and to IV gammaglobulin predict response to subsequent splenectomy?. 67. 2001
A pilot study of rhuIL-11 treatment of refractory ITP.. 66. 2001
Prevalence of HTLV-I-associated T-cell lymphoma.. 66. 2001
Role of transforming growth factor beta1 in microvascular endothelial cell apoptosis associated with thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome.. 66. 2001
Is it necessary to test patients with immune thrombocytopenic purpura (ITP) for seropositivity to HTLV-1?. 61. 1999
Serum transferrin receptor as a marker of erythropoiesis suppression in patients on chronic transfusion.. 60. 1999
Role of caspases 1 and 3 and Bcl-2-related molecules in endothelial cell apoptosis associated with thrombotic microangiopathies.. 59. 1998
Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura.. 57. 1998
Dissection of the association status of two polymorphisms in the beta-globin gene cluster with variations in F-cell number in non-anemic individuals.. 56. 1997
Pilot study of 5-azacytidine (5-AZA) and carboplatin (CBDCA) in patients with relapsed/refractory leukemia.. 51. 1996
Haplotypes of the human beta-like globin gene cluster: analyzing the 3' Hpa I polymorphic site by long distance PCR.. 50. 1995
Allogeneic bone marrow transplantation for leukemia following piperazinedione and fractionated total body irradiation.. 46. 1994
Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients.. 44. 1993
Synergistic effect of heme and IL-1 on hematopoietic stromal regeneration after radiation.. 44. 1993
Elevated levels of heme oxygenase-1 activity and mRNA in peripheral blood adherent cells of acquired immunodeficiency syndrome patients.. 43. 1993
Phorbol ester-induced hairy cell features on chronic lymphocytic leukemia cells in vitro.. 40. 1992
Protein C and S levels in acute leukemia.. 37. 1991
Alternation of two doses of intravenous gammaglobulin in the maintenance treatment of patients with immune thrombocytopenic purpura: more is not always better.. 33. 1990
Isolated thrombocytopenia in patients infected with HIV: treatment with intravenous gammaglobulin.. 28. 1988
Clonal immunoglobulin gene rearrangements in chronic lymphocytic leukemia: a correlative study.. 27. 1988
The first report of familial adult T-cell leukemia lymphoma in the United States.. 27. 1988
Measurement of terminal deoxynucleotidyl transferase mRNA in clinical samples: a new parameter in analysis of leukemia cells.. 25. 1987
Porphyria cutanea tarda associated with the acquired immune deficiency syndrome.. 25. 1987
Phenotypic heterogeneity of human T-cell malignancies: demonstration by monoclonal antibodies and cytochemical markers.. 12. 1982
Plasma beta-thromboglobulin values in thrombocytopenic patients with acute leukemia.. 8. 1980
Relationship of SV40 T-antigen expression in vitro to disorders of bone marrow function.. 8. 1980
Subpopulations of human peripheral blood cells: analysis of granulocytic progenitor cells by flow cytometry and immunologic surface markers.. 7. 1979
Coulter S hematocrit and microhematocrit in polycythemic patients.. 5. 1978
Guidelines for protocol studies in chronic lymphocytic leukemia.. 4. 1978
The treatment of combination chemotherapy-resistant Hodgkin disease with single-agent vinblastine.. 4. 1978
Effect of prior radiotherapy on tolerance and response to chemotherapy in non-Hodgkin's lymphoma.. 2. 1977
SV40 T-antigen expression in skin fibroblasts from clinically normal individuals and from ten cases of Fanconi anemia.. 2. 1977
Two p53s in a Pod: Co-occurring plasma cell myeloma and therapy-related myeloid neoplasm following lenalidomide therapy. 2023
Myelodysplastic syndromes with no somatic mutations detected by next-generation sequencing display similar features to myelodysplastic syndromes with detectable mutations. 2021
Survival of patients with marginal zone lymphoma in the United States: A population-based cohort study (2000 to 2017).. 96. 2021
Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just the bone marrow?. 95. 2020
Accelerated thrombin times are associated with thrombotic risk.. 95. 2020
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group.. 95. 2019
Monoclonal gammopathy-associated thrombotic microangiopathy.. 94. 2019
Maternal sensitization occurs before delivery in severe cases of fetal alloimmune thrombocytopenia.. 94. 2019
Response to thrombopoietic agents is related to on-treatment bone marrow megakaryocyte morphology in patients with chronic immune thrombocytopenia.. 94. 2019
Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group.. 94. 2019
Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid-directed monoclonal antibody.. 91. 2016
Lenalidomide in the treatment of Rosai Dorfman disease--a first in use report.. 91. 2016
Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium.. 89. 2014
Successful perioperative use of prothrombin complex concentrate in the treatment of acquired factor X deficiency in the setting of systemic light-chain (AL) amyloidosis.. 89. 2014
Skin necrosis induced by generic enoxaparin.. 88. 2013
Localized insulin-derived amyloidosis: a potential pitfall in the diagnosis of systemic amyloidosis by fat aspirate.. 87. 2012
Thrombotic thrombocytopenic purpura complicating immune thrombocytopenic purpura--a case report.. 86. 2011
Venous thrombosis associated with gene deletion of tissue factor pathway inhibitor.. 84. 2009
Allopurinol-induced pure red cell aplasia.. 73. 2003
Idiopathic thrombocytopenic purpura.. 48. 1995
Acquired platelet storage pool deficiency due to severe valvular disease corrected by prosthetic valve replacement.. 45. 1994
Does absence of intracranial hemorrhage in the first pregnancy in fetal and neonatal alloimmune thrombocytopenia preclude occurrence in the second? 2024
Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial. 2023
Hematological support of patients with significant anemia who decline red blood cell blood transfusion. 2022
Clinical Features Associated with Thrombotic Events in Children with Myeloproliferative Neoplasms. 2022
Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. 2022
Landscape and clinical significance of long non-coding RNAs involved in multiple myeloma expressed fusion transcripts. 2021
Multicenter evaluation of efficacy and toxicity of venetoclax-based combinations in patients with accelerated and blast phase myeloproliferative neoplasms. 2021
Serologic response to mRNA COVID-19 vaccination in lymphoma patients. 2021
Iron overload after complement inhibitor treatment of Paroxysmal Nocturnal Hemoglobinuria. 2021
The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy. 2021
Outcomes in CLL patients with NOTCH1 regulatory pathway mutations. 2021
Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The FERWON-IDA/NEPHRO trials. 2020
Characterization of the severe phenotype of pyruvate kinase deficiency. 2020
Clinical and economic burden of regularly transfused adult patients with β-thalassemia in the United States: A retrospective cohort study using payer claims. 2019
Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. 2012
Fatal CMV pneumonitis in a lymphoma patient treated with rituximab. 2009
A novel beta-thalassemia intermedia phenotype containing Nt494+129T-->C and NT494+132C-->A mutations in cis and a Nt168C-->T (beta(o) 39 point) mutation in trans. 2001
Cerebral fat embolism syndrome mimicking thrombotic thrombocytopenic purpura in a patient with hemoglobin SC disease. 2016
Reality of complementary and alternative medicine in lymphoma patients: hope, hype, or help?. 84. 2009
Modern management of respiratory failure due to pulmonary mycoses following allogeneic hematopoietic stem-cell transplantation. 2005
Mortality in immune thrombocytopenic purpura: report of seven cases and consideration of prognostic indicators. 1994
Lymphomas following cardiac transplantation. Case report and review of the literature. 1991
CARs of the future. 2019
Determination of human platelet antigen typing by molecular methods: Importance in diagnosis and early treatment of neonatal alloimmune thrombocytopenia. 2012
Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond. 2008
Benzene-induced acute myeloid leukemia: a clinician's perspective. 2007

VIVO Weill Cornell Medical College

American journal of hematology Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)